CBER 2024 Priorities (8:15AM-8:45AM)
FDA CBER Director Peter Marks
Advisory Committees: What Does It All Mean? (8:45AM-9:45AM)
FDA Oncology Center of Excellence Director Richard Pazdur
CBER Deputy Director Celia witten
FDA Office of new drugs director Peter stein
johns hopkins university’s caleb alexander
BREAK (9:45AM-10AM)
FDA OCE Reunion (10AM-11AM)
FDA Oncology Center of Excellence Director Richard Pazdur
parexel oncology center of excellence global head amy mckee
treeline biosciences svp-clinical development julia beaver
pi health ceo geoffrey kim
merck Vp-oncology clinical development gideon blumenthal
FDA Then And Now (11AM-11:30AM)
former FDA Principal Deputy Commissioner Janet woodcock
Drug Payment and Access In 2024 (11:30AM-12:30PM)
CMS/CMMI Deputy Director ellen lukens
Maryland rx drug affordability board exec director andrew york
arm vp-government affairs erica cischke
national health council vp-policy jennifer dexter
salo health strategies ceo matt salo
ADVI’s Hillary Cavanagh